Marc Lémann
Impact in
- Genetics top 0.05%
- Inflammatory Bowel Disease
- Genetic Associations and Epidemiology
- Gastroenterology top 0.5%
- Gastrointestinal motility and disorders
Papers in
- Genetics 135
- Inflammatory Bowel Disease 132
-
- Gastrointestinal motility and disorders 23
- Co-authors
- Jean-Frederic Colombel (30 shared papers)Yoram Bouhnik (44 shared papers)R Modigliani (37 shared papers)Jean‐Yves Mary (20 shared papers)Laurent Peyrin‐Biroulet (12 shared papers)Philippe R. Marteau (25 shared papers)Geert D’Haens (15 shared papers)Simon P.L. Travis (8 shared papers)
- Journals
- Gastroenterology (40 papers)Alimentary Pharmacology & Therapeutics (16 papers)The American Journal of Gastroenterology (16 papers)Gut (15 papers)Inflammatory Bowel Diseases (15 papers)
- Partner nations
- FranceBelgiumUnited States
In The Last Decade
Marc Lémann
212 papers receiving 22k citations
Marc Lémann's Hit Papers
Peers
Comparison fields: 5 of 145
- Genetics 15k
- Gastroenterology 1k
- Rheumatology 1k
- Pathology and Forensic Medicine 1k
- Immunology 1k
Countries citing papers authored by Marc Lémann
This map shows the geographic impact of Marc Lémann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Lémann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Lémann more than expected).
Fields of papers citing papers by Marc Lémann
This network shows the impact of papers produced by Marc Lémann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Lémann. The network helps show where Marc Lémann may publish in the future.
Co-authors
The 25 scholars most cited alongside Marc Lémann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 218 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci Hit paper breakdown → | 2010 | 2131 |
| 2 | The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management Hit paper breakdown → | 2010 | 1245 |
| 3 | Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47 Hit paper breakdown → | 2011 | 1146 |
| 4 | Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility Hit paper breakdown → | 2019 | 1067 |
| 5 | A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis Hit paper breakdown → | 2006 | 1007 |
| 6 | Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study Hit paper breakdown → | 2009 | 894 |
| 7 | European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease Hit paper breakdown → | 2009 | 658 |
| 8 | Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registry Hit paper breakdown → | 2009 | 520 |
| 9 | Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) Hit paper breakdown → | 2011 | 517 |
| 10 | Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial Hit paper breakdown → | 2012 | 513 |
| 11 | Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped Hit paper breakdown → | 2011 | 499 |
| 12 | Development of the Crohnʼs disease digestive damage score, the Lémann score Hit paper breakdown → | 2010 | 488 |
| 13 | 2006 | 478 | |
| 14 | 2008 | 434 | |
| 15 | Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease Hit paper breakdown → | 2011 | 413 |
| 16 | 2009 | 403 | |
| 17 | 1996 | 391 | |
| 18 | 2010 | 359 | |
| 19 | 2005 | 345 | |
| 20 | 2006 | 304 |
About Marc Lémann
Marc Lémann is a scholar working on Genetics, Gastroenterology, Rheumatology, Epidemiology and Nutrition and Dietetics, having authored 218 papers that have together received 22.9k indexed citations. Recurring topics across this work include Inflammatory Bowel Disease (132 papers), Gastrointestinal motility and disorders (23 papers), Clinical Nutrition and Gastroenterology (7 papers), Pregnancy and Medication Impact (7 papers), Rheumatoid Arthritis Research and Therapies (7 papers), Tuberculosis Research and Epidemiology (6 papers), Hematopoietic Stem Cell Transplantation (5 papers) and Autoimmune and Inflammatory Disorders (4 papers). The work is most often cited by research in Genetics (15k citations), Gastroenterology (1k citations), Rheumatology (1k citations), Pathology and Forensic Medicine (1k citations) and Immunology (1k citations). Marc Lémann has collaborated with scholars based in France, Belgium and United States. Frequent co-authors include Jean-Frederic Colombel, Yoram Bouhnik, R Modigliani, Jean‐Yves Mary, Laurent Peyrin‐Biroulet, Philippe R. Marteau, Geert D’Haens, Simon P.L. Travis, Jacques Cosnes and Antoine Cortot. Their work appears in journals such as Gastroenterology, Alimentary Pharmacology & Therapeutics, The American Journal of Gastroenterology, Gut and Inflammatory Bowel Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.